With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments. Read more
Could the Daunting Biology of Small-Cell Lung Cancer Provide the Key to Elucidating Drug Resistance?
At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon. Read more
When compensating participants in clinical trials, the objective is to show appreciation and consideration for a patient’s time and expenses without exerting undue influence. The Office for Human Research Protections […] Read more
In September 2017, the US Food and Drug Administration (FDA) approved bevacizumab-awwb for the treatment of NSCLC, with the same indications as the tradename. Although bevacizumab-awwb is the only biosimilar […] Read more
Liquid biopsies have also opened new perspectives in the field to which Blackhall has dedicated much of her research career. “I would like to use this award to highlight the […] Read more
Vansteenkiste leads the Respiratory Oncology Unit at University Hospitals Leuven, where he has been involved in approximately 300 lung cancer trials. He has served on the editorial boards of numerous […] Read more
Lung cancer is one of the most common cancers worldwide, with more than 2 million people diagnosed each year.1 Advances in early detection and treatment have resulted in more people […] Read more
The COVID-19 pandemic has had a devastating effect on lung cancer outcomes in the United Kingdom (UK). Fewer people have presented or have been referred for investigation, and those who […] Read more
Discovery of targetable genomic alterations, including mutations of EGFR, have resulted in improved survival for patients with non-small cell lung cancer (NSCLC).1 Although many patients experience robust responses to EGFR-targeted […] Read more
A middle-aged woman walks into the clinic using her right hand to hold her shirt away from her chest. “Even just my shirt brushing against my skin hurts,” she says […] Read more